INSIGHT. Obesity is one of the fastest-growing public health challenges of our time. More than a billion people are estimated to be living with the disease globally today, a number that is expected to keep rising. The consequences are significant for individuals, healthcare systems and society as a whole. At
INSIGHT. Cancer treatment has long focused on removing or destroying visible tumours, with limited ways to confirm whether all cancer cells were truly gone. Even after successful treatment, small numbers of cells can persist and later cause relapse. While liquid biopsy has been used in oncology for several years, recent
NEWS. Sciety has contributed to raising SEK 25 million for healthtech company Braive as part of the company’s latest round, totalling SEK 30 million. Braive has developed an AI-based, clinically validated platform for mental health treatment that enables more efficient, scalable, and measurable care. The capital will fund further development
PRESS RELEASE. Sciety portfolio company Saga Diagnostics has entered into an agreement to be acquired by Foundation Medicine, Inc., a global precision medicine company and an independent subsidiary of Roche, for a deal value of up to USD 595 million, including commercial and regulatory milestone payments. Saga Diagnostics is a
INSIGHT. Traditional medicine has long relied on three pillars: removing, repairing, or replacing damaged tissue. A fourth pillar is now emerging: regenerative medicine. Rather than treating symptoms, regenerative medicine aims to restore the body’s function by stimulating its own healing capacity, potentially reducing the need for prosthetics, transplants, and long-term
PRESS RELEASE. Sciety has led a 36 MSEK funding round in the healthtech company Everdrone. The company operates and develops an autonomous drone service for time-critical medical transport, including the delivery of automated external defibrillators (AEDs) directly to patients in cardiac arrest. Everdrone’s customers include Västra Götaland Region, Region Stockholm
Sciety is a capital partner specialising in life science and healthcare, offering services in capital raising and related areas. Sciety may currently have, may previously have had or may in the future be engaged by companies mentioned in our communications or operating in the sectors described, and may hold ownership interests in such companies. Sciety receives remuneration for its services, including commissions in connection to capital raises. Our communication is intended for informational purposes only and does not constitute personal investment advice. We do not guarantee the accuracy, completeness or timeliness of the information provided. Investment decisions should not be based solely on this communication.